Xact Kapitalforvaltning’s AnaptysBio ANAB Stock Holding History

Xact Kapitalforvaltning’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,400	Closed	-$248K	–	1440
2019 Q1	$248K	Hold	3,400	–	–	0.01%	1317
2018 Q4	$217K	Hold	3,400	–	–	0.01%	1406
2018 Q3	$339K	Hold	3,400	–	–	0.01%	1275
2018 Q2	$242K	Buy	+3,400	New	+$285K	0.01%	1468

Other funds holding ANAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Xact Kapitalforvaltning's ANAB Position: Q2 2019 in Review

Xact Kapitalforvaltning sold out of AnaptysBio (ANAB) in Q2 2019, closing a stake of 3,400 shares — an estimated $248K sold.

Xact Kapitalforvaltning first reported a position in ANAB in Q2 2018 and held it in 4 quarters. The position peaked at $339K in Q3 2018. 127 funds tracked by Wall St. Rank hold ANAB as of Q2 2019.

Xact Kapitalforvaltning reported no remaining AnaptysBio position as of Q2 2019 after selling out during the quarter.
Xact Kapitalforvaltning sold 3,400 AnaptysBio shares in Q2 2019, an estimated $248K.
Xact Kapitalforvaltning first reported a position in AnaptysBio in Q2 2018 and held it in 4 quarters.
Xact Kapitalforvaltning's AnaptysBio position peaked at $339K in Q3 2018.
127 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2019.

Based on Xact Kapitalforvaltning's 13F filing for Q2 2019, filed 12 Jul 2019.